Helper function of memory CD8+ T cells: Heterologous CD8 + T cells support the induction of therapeutic cancer immunity

Cancer Research

Volumn 67, Issue 20, 2007, Pages 10012-10018

  Nakamura, Yutaro ^a,f   Watchmaker, Payal ^a   Urban, Julie ^a   Sheridan, Brian ^b   Giermasz, Adam ^a   Nishimura, Fumihiko ^c   Sasaki, Kotaro ^c   Cumberland, Rachel ^a   Muthuswamy, Ravikumar ^a   Mailliard, Robbie B ^a   Larregina, Adriana T ^c   Falo, Louis D ^c   Gooding, William ^e   Storkus, Walter J ^c,e   Okada, Hideho ^a,b   Hendricks, Robert L ^b,d   Kalinski, Pawel ^a,b,c,e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d University of Pittsburgh School of Medicine   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; PROTEIN P70;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION;

ADENOCARCINOMA; ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; DENDRITIC CELLS; FEMALE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 35448963393     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1735     Document Type: Article

References (37)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
2. Schreckenberger C, Kaufmann AM. Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol 2004;16:485-91.
3. Spearman P. Current progress in the development of HIV vaccines. Curr Pharm Des 2006;12:1147-67.
4. Srivastava PK. Therapeutic cancer vaccines. Curr Opin Immunol 2006;18:201-5.
5. Sprent J, Surh CD. T cell memory. Annu Rev Immunol 2002;20:551-79.
6. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002;2:251-62.
7. + T cells. Trends Immunol 2003;24:404-7.
8. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004;25:98-104.
9. + T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 2005;11:748-56.
10. + T lymphocytes. Nature 2003;421:852-6.
11. Hirschhorn K, Bach F, Kolodny RL, Firschein IL, Hashem N. Immune response and mitosis of human peripheral blood lymphocytes in vitro. Science 1963;142:1185-7.
12. Gershon RK, Cohen P, Hencin R, Liebhaber SA. Suppressor T cells. J Immunol 1972;108:586-90.
13. + T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 2000;164:3095-101.
14. + T cells in vivo. Proc Natl Acad Sci U S A 2006;103:147-52.
15. Wong P, Pamer EG. Feedback regulation of pathogen-specific T cell priming. Immunity 2003;18:499-511.
16. + T cells. J Immunol 2000;165:915-24.
17. + T cells: CD4-independent help. J Immunol 2001;167:1283-9.
18. + T cells in the development of T helper type 1 responses. J Exp Med 2002;195:473-83.
19. Thomas MJ, Noble A, Sawicka E, Askenase PW, Kemeny DM. CD8 T cells inhibit IgE via dendritic cell IL-12 induction that promotes Th1 T cell counterregulation. J Immunol 2002;168:216-23.
20. Ronchese F, Hermans IF. Killing of dendritic cells: a life cut short or a purposeful death? J Exp Med 2001;194:F23-6.
21. Medema JP, Schuurhuis DH, Rea D, et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med 2001;194:657-67.
22. Ruedl C, Kopf M, Bachmann MF. CD8(+) T cells mediate CD40-independent maturation of dendritic cells in vivo. J Exp Med 1999;189:1875-84.
23. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
24. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD, Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996;2:1122-8.
25. Son YI, Egawa S, Tatsumi T, Redlinger RE, Jr., Kalinski P, Kanto T. A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J Immunol Methods 2002;262:145-57.
26. Fraser JD. T-cell recognition of superantigens. Res Immunol 1993;144:173-4.
27. Kalinski P, Smits HH, Schuitemaker JH, et al. IL-4 is a mediator of IL-12p70 induction by human Th2 cells: reversal of polarized Th2 phenotype by dendritic cells. J Immunol 2000;165:1877-81.
28. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-52.
29. Carbone FR, Sterry SJ, Butler J, Rodda S, Moore MW. T cell receptor α-chain pairing determines the specificity of residue 262 within the Kb-restricted, ovalbumin257-264 determinant. Int Immunol 1992;4:861-7.
30. Hochrein H, O'Keeffe M, Luft T, et al. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med 2000;192:823-33.
31. Semenzato G, Pezzutto A, Agostini C, Albertin M, Gasparotto G. T-lymphocyte subpopulations in chronic lymphocytic leukemia: a quantitative and functional study. Cancer 1981;48:2191-7.
32. Tsukishiro T, Donnenberg AD, Whiteside TL. Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother 2003;52:599-607.
33. Maczek C, Berger TG, Schuler-Thurner B, et al. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients. Int J Cancer 2005;115:450-5.
34. Mueller SN, Jones CM, Stock AT, Suter M, Heath WR, Carbone FR. CD4+ T cells can protect APC from CTL-mediated elimination. J Immunol 2006;176:7379-84.
35. + T-helper and a T-killer cell. Nature 1998;393:474-8.
36. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-80.
37. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-40L interactions. Nature 1998;393:480-3.